These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

474 related articles for article (PubMed ID: 26950313)

  • 1. Effects of long-term tenofovir-based combination antiretroviral therapy in HIV-hepatitis B virus coinfection on persistent hepatitis B virus viremia and the role of hepatitis B virus quasispecies diversity.
    Audsley J; Bent SJ; Littlejohn M; Avihingsanon A; Matthews G; Bowden S; Bayliss J; Luciani F; Yuen L; Fairley CK; Locarnini S; Lewin SR; Sasadeusz J
    AIDS; 2016 Jun; 30(10):1597-606. PubMed ID: 26950313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and causes of suboptimal response to tenofovir-based therapy in individuals coinfected with HIV and hepatitis B virus.
    Matthews GV; Seaberg EC; Avihingsanon A; Bowden S; Dore GJ; Lewin SR; Sasadeusz J; Revill PA; Littlejohn M; Hoy JF; Finlayson R; Ruxrungtham K; Saulynas M; Locarnini S; Thio CL
    Clin Infect Dis; 2013 May; 56(9):e87-94. PubMed ID: 23315316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications.
    Boyd A; Gozlan J; Maylin S; Delaugerre C; Peytavin G; Girard PM; Zoulim F; Lacombe K
    Hepatology; 2014 Aug; 60(2):497-507. PubMed ID: 24752996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons.
    Bihl F; Martinetti G; Wandeler G; Weber R; Ledergeber B; Calmy A; Battegay M; Cavassini M; Vernazza P; Caminada AP; Rickenbach M; Bernasconi E;
    BMC Gastroenterol; 2015 Jul; 15():79. PubMed ID: 26152237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term TDF-Inclusive ART and Progressive Rates of HBsAg Loss in HIV-HBV Coinfection-Lessons for Functional HBV Cure?
    Audsley J; Avihingsanon A; Littlejohn M; Bowden S; Matthews GV; Fairley CK; Lewin SR; Sasadeusz J
    J Acquir Immune Defic Syndr; 2020 Aug; 84(5):527-533. PubMed ID: 32692112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virological Response to Tenofovir Disoproxil Fumarate in HIV-Positive Patients with Lamivudine-Resistant Hepatitis B Virus Coinfection in an Area Hyperendemic for Hepatitis B Virus Infection.
    Huang YS; Chang SY; Sheng WH; Sun HY; Lee KY; Chuang YC; Su YC; Liu WC; Hung CC; Chang SC
    PLoS One; 2016; 11(12):e0169228. PubMed ID: 28033344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lamivudine Monotherapy-Based cART Is Efficacious for HBV Treatment in HIV/HBV Coinfection When Baseline HBV DNA <20,000 IU/mL.
    Li Y; Xie J; Han Y; Wang H; Zhu T; Wang N; Lv W; Guo F; Qiu Z; Li Y; Du S; Song X; Thio CL; Li T
    J Acquir Immune Defic Syndr; 2016 May; 72(1):39-45. PubMed ID: 26745828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lamivudine plus tenofovir versus lamivudine plus adefovir for the treatment of hepatitis B virus in HIV-coinfected patients, starting antiretroviral therapy.
    Sarkar J; Saha D; Bandyopadhyay B; Saha B; Chakravarty R; Guha SK
    Indian J Med Microbiol; 2018; 36(2):217-223. PubMed ID: 30084414
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term hepatitis B virus dynamics in HIV-hepatitis B virus-co-infected patients treated with tenofovir disoproxil fumarate.
    Lacombe K; Gozlan J; Boelle PY; Serfaty L; Zoulim F; Valleron AJ; Girard PM
    AIDS; 2005 Jun; 19(9):907-15. PubMed ID: 15905671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of combination hepatitis B therapy in HIV/HBV coinfected antiretroviral naïve individuals in Thailand.
    Matthews GV; Avihingsanon A; Lewin SR; Amin J; Rerknimitr R; Petcharapirat P; Marks P; Sasadeusz J; Cooper DA; Bowden S; Locarnini S; Ruxrungtham K; Dore GJ
    Hepatology; 2008 Oct; 48(4):1062-9. PubMed ID: 18697216
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liver fibrosis regression and progression during controlled hepatitis B virus infection among HIV-HBV patients treated with tenofovir disoproxil fumarate in France: a prospective cohort study.
    Boyd A; Bottero J; Miailhes P; Lascoux-Combe C; Rougier H; Girard PM; Serfaty L; Lacombe K
    J Int AIDS Soc; 2017 Feb; 20(1):21426. PubMed ID: 28362068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term virological and serologic responses of chronic hepatitis B virus infection to tenofovir disoproxil fumarate-containing regimens in patients with HIV and hepatitis B coinfection.
    Huang YS; Sun HY; Chang SY; Chuang YC; Cheng A; Huang SH; Huang YC; Chen GJ; Lin KY; Su YC; Liu WC; Hung CC
    Hepatol Int; 2019 Jul; 13(4):431-439. PubMed ID: 31177505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV-HBV coinfection in Southern Africa and the effect of lamivudine- versus tenofovir-containing cART on HBV outcomes.
    Hamers RL; Zaaijer HL; Wallis CL; Siwale M; Ive P; Botes ME; Sigaloff KC; Hoepelman AI; Stevens WS; Rinke de Wit TF;
    J Acquir Immune Defic Syndr; 2013 Oct; 64(2):174-82. PubMed ID: 23892239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV-coinfected patients from Côte d'Ivoire.
    Boyd A; Moh R; Gabillard D; le Carrou J; Danel C; Anglaret X; Eholié SP; Maylin S; Delaugerre C; Zoulim F; Girard PM; Lacombe K;
    Antivir Ther; 2015; 20(6):643-54. PubMed ID: 25852125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Similar evolution of hepatitis B virus quasispecies in patients with incomplete adefovir response receiving tenofovir/emtricitabine combination or tenofovir monotherapy.
    Lavocat F; Dény P; Pichoud C; Al Hawajri N; Kitrinos K; Borroto-Esoda K; Zoulim F
    J Hepatol; 2013 Oct; 59(4):684-95. PubMed ID: 23742912
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tenofovir-based combination therapy for HIV/HBV co-infection: factors associated with a partial HBV virological response in patients with undetectable HIV viraemia.
    Childs K; Joshi D; Byrne R; Bruce M; Carey I; Agarwal K; Taylor C
    AIDS; 2013 Jun; 27(9):1443-8. PubMed ID: 23435302
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in HIV/HBV-Coinfected Patients in the Tenofovir Era Are Greatly Affected by Immune Suppression.
    Huang AJ; Núñez M
    J Int Assoc Provid AIDS Care; 2015; 14(4):360-8. PubMed ID: 25999329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort co-infected with human immunodeficiency virus.
    Stephan C; Berger A; Carlebach A; Lutz T; Bickel M; Klauke S; Staszewski S; Stuermer M
    J Antimicrob Chemother; 2005 Dec; 56(6):1087-93. PubMed ID: 16269552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged use of tenofovir in HIV/hepatitis B virus (HBV)-coinfected individuals does not lead to HBV polymerase mutations and is associated with persistence of lamivudine HBV polymerase mutations.
    Audsley J; Arrifin N; Yuen LK; Ayres A; Crowe SM; Bartholomeusz A; Locarnini SA; Mijch A; Lewin SR; Sasadeusz J
    HIV Med; 2009 Apr; 10(4):229-35. PubMed ID: 19178592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies.
    Wandeler G; Mauron E; Atkinson A; Dufour JF; Kraus D; Reiss P; Peters L; Dabis F; Fehr J; Bernasconi E; van der Valk M; Smit C; Gjærde LK; Rockstroh J; Neau D; Bonnet F; Rauch A;
    J Hepatol; 2019 Aug; 71(2):274-280. PubMed ID: 30965070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.